Strongest evidence
Visceral abdominal fat
Randomized trials reported roughly 15% to 20% reductions in visceral fat over 6 to 12 months in a specific HIV population.
COA VerifiedHormonal Peptides
Buy Tesamorelin in Canada: 5mg and 10mg Research Vials
5.03 reviews
● In stock — ships next business day$140.00
Purchase option
Strength
Buy more, save more
2+ vialsSave 5%
5+ vialsSave 10%
10+ vialsSave 15%
Not in stock yet. Leave your email and we will tell you when it is available.
Get notified when it's availableIndependently lab tested — 99%+ purity
COA number printed on every vial
Ships next business day, 1–3 day delivery
Discreet packaging · Interac e-Transfer
Tesamorelin is a growth-hormone-releasing-hormone analogue studied in growth-hormone secretion and visceral-fat-metabolism research. Each vial is lyophilized and independently tested. For research purposes only.
Store lyophilized vials refrigerated and protected from light and moisture. Follow the product-specific storage record after reconstitution.
Orders ship from within Canada in discreet packaging. Express delivery is typically 1–3 business days after dispatch.
Standard returns are not accepted because research materials cannot be safely restocked after delivery. Contact support promptly about damaged, incorrect, or compromised items.
Reconstitution calculator
Turn the vial amount into an easy-to-read volume
Enter three known values. The calculator converts the total vial amount and water added into a concentration, then shows the liquid volume and equivalent U-100 syringe units for the quantity entered.
The calculator does not choose a quantity. It converts the quantity you enter. One milligram equals 1,000 micrograms.
Bacteriostatic water is generally the most appropriate choice for multi-use research preparation because it contains a preservative for repeated vial access.
Concentration5 mg/mL0.5 mg in each 0.1 mL
Calculated liquid volume0.2 mL20 units on a U-100 syringe
Example using the values above: 10mg with 2mL of water equals 5mg/mL. A 1mg quantity equals 0.2mL, or 20 U-100 units.
Tesamorelin buyer and evidence guide
Understanding Tesamorelin: Visceral-Fat Evidence, Expectations and Vial Choice
Tesamorelin is most often compared by buyers focused on visceral abdominal fat, body composition, and growth-hormone signaling. Unlike many wellness peptides, it has randomized human outcome data and an authorized prescription formulation for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
That evidence is specific to the population and formulation studied, but it makes the buyer conversation more concrete: Tesamorelin has stronger visceral-fat evidence than general weight-loss evidence, and the 5mg versus 10mg product choice is about total material and purchase value rather than one vial being a stronger version.
Not the same goal
Not general scale weight loss
The main clinical effect was visceral-fat reduction, with less emphasis on total body-weight change.
Mechanism
GHRH, GH, and IGF-1
Tesamorelin stimulates the GHRH receptor and raises downstream GH and IGF-1 signaling.
Product decision
5mg vs 10mg
The smaller vial lowers upfront cost; the larger vial contains twice the same listed compound.
Product specifications
- Research name
- Tesamorelin
- Compound class
- Growth-hormone-releasing-hormone analogue
- Research targets
- GHRH or growth-hormone-releasing-factor receptor
- Available strength
- 5mg and 10mg
- Form
- Lyophilized powder in a vial
- Documentation
- The listing identifies independent testing and COA availability
- Dispatch country
- Canada
- Intended use
- Laboratory and in-vitro research only
Tesamorelin clinical evidence at a glance
Human evidence is strongest for visceral-fat reduction in adults with HIV-associated abdominal fat accumulation.
| Evidence | Population and duration | What was reported | Buyer takeaway |
|---|---|---|---|
| Randomized efficacy and extension trial | 404 adults with HIV-associated abdominal fat, 6 to 12 months | About 10.9% VAT reduction at 6 months and roughly 18% among continuers at 12 months | Strong condition-specific evidence |
| JAMA liver-fat trial | 50 adults with HIV and abdominal fat, 6 months | Reduced visceral and liver fat versus placebo | Supports targeted fat-distribution effects |
| Withdrawal observation | Participants switched from Tesamorelin to placebo | Visceral-fat improvements were rapidly lost | The studied effect was not shown to persist after stopping |
The cited trials used specific pharmaceutical formulations and monitored populations. They do not verify a separately sourced vial.
What is Tesamorelin and what outcome is it best known for?
Tesamorelin is a 44-amino-acid modified GHRH analogue. Its best-established human outcome is reduction of visceral abdominal fat in adults with HIV-associated lipodystrophy, not broad fat loss in every population and not a bodybuilding outcome.
Visceral fat sits around internal organs and is different from the pinchable subcutaneous fat beneath the skin. Controlled studies reported reductions in visceral-fat area and waist-related measurements, while body-weight change was not the defining result.
What the human studies reported and what to expect
In a 404-person randomized study, visceral fat decreased about 10.9% at six months versus 0.6% with placebo, and participants who continued reached roughly 18% at 12 months. Improvements were lost relatively quickly after participants switched from Tesamorelin to placebo, which supports viewing the effect as dependent on continued exposure in the study context.
Tesamorelin raises IGF-1, and monitored studies tracked glucose, swelling, joint symptoms, injection-site reactions, and other adverse effects. The most relevant expectation is a targeted body-composition effect over months, not immediate weight loss or a guaranteed cosmetic change.
Tesamorelin compared with CJC-1295 / Ipamorelin
The products both appear in GH-axis research but have different compositions.
| Product | Composition | Research pathway | Bison format |
|---|---|---|---|
| Tesamorelin | Single GHRH analogue | GHRH receptor | 5mg, 10mg |
| CJC-1295 / Ipamorelin | Two-component blend | GHRH plus secretagogue pathways | 10mg total |
Tesamorelin has the clearer visceral-fat outcome evidence. CJC-1295 / Ipamorelin offers two upstream pathways but substantially less direct human evidence for body-composition, recovery, or sleep outcomes.
Tesamorelin versus CJC-1295 / Ipamorelin
Tesamorelin is the clearer evidence-led choice when the buyer's specific question is visceral abdominal fat. Its human trials measured that outcome directly in defined populations and used an authorized drug formulation.
CJC-1295 / Ipamorelin may appeal to someone comparing broader GH-axis, recovery, or sleep-related hypotheses and wanting two pathways in one vial. The tradeoff is much less direct human evidence for those outcomes and uncertainty about the exact blend format or ratio.
5mg vs 10mg Tesamorelin: which vial fits the purchase?
The 5mg and 10mg labels describe total Tesamorelin in the vial. Both list the same compound. The 10mg vial contains twice the total material, but it is not automatically a stronger individual amount.
For a first purchase, 5mg is the lower-cost way to evaluate the product documentation and format while limiting potential unused material. Choose 10mg when you already know you need the larger total quantity and the displayed price per milligram supports the bigger vial.
How to evaluate Tesamorelin quality before buying
The listing identifies independent testing and COA availability. Before ordering, confirm that the available certificate identifies the compound or blend, batch or lot, test date, analytical method, and reported result. After delivery, compare the vial label with that exact documentation rather than relying on a generic certificate.
Identity, purity, fill quantity, sterility, and endotoxin testing answer different questions. A large purity percentage does not prove every other quality attribute, so buyers should check which tests are actually reported and avoid assuming that an unlisted result was performed.
Research-use and approval status
The Bison Peptides Tesamorelin vial is supplied as a technical laboratory research material, not an authorized prescription formulation. The page summarizes published research to help buyers understand the compound, evidence, and product format; it is not an individual treatment or dosing recommendation.
Related research pages
Primary sources and status references
- PubMed: Randomized Tesamorelin visceral-fat trial
- PubMed: Tesamorelin visceral-fat and liver-fat trial
- FDA: Current Egrifta WR prescribing information
- FDA: Tesamorelin mechanism and product description
- Health Canada: Warning about unauthorized peptide products
Content reviewed August 11, 2026 by the Bison Peptides editorial team.
Reviews
5.03 reviews
Great 10mg option
“I chose the 10mg Tesamorelin and the entire purchase went smoothly. The product arrived well protected with a clean, easy-to-read label. I also appreciated being able to choose between two strengths depending on what I needed. Very good experience overall.”
10mg ·
Matthew V. · Verified buyer
Exactly as pictured
“My 5mg vial arrived looking exactly like the photos on the website. Packaging was secure and everything was clearly identified. It's a small detail, but I appreciate when a company puts effort into presentation and doesn't just send an unmarked vial.”
5mg ·
Adam E. · Verified buyer
Second order was just as good
“This was my second Tesamorelin order and both experiences have been consistent. The 10mg vial arrived safely, the packaging was neat, and communication throughout the order was good. It's nice knowing what to expect each time you purchase.”
10mg ·
Luke R. · Verified buyer
Frequently asked questions
What is Tesamorelin best known for?
Tesamorelin is best known for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Randomized trials measured visceral-fat area, waist-related outcomes, and related metabolic markers over 6 to 12 months.
Does Tesamorelin cause general weight loss?
Its strongest evidence is for changing visceral-fat distribution, not producing the broad scale-weight reductions seen in GLP-1 obesity trials. A person can have less visceral fat without an equally large change in total body weight.
How long did Tesamorelin studies take to show results?
Key trials measured changes at about 6 months and 12 months. The evidence supports a gradual body-composition effect over months, not an immediate result.
What is the difference between 5mg and 10mg Tesamorelin?
The difference is total material in the vial. The 10mg vial contains twice as much Tesamorelin as the 5mg vial. It is not a different compound or automatically a stronger individual amount.
Which Tesamorelin vial is better for a first purchase?
The 5mg vial is usually the more practical first purchase because it costs less up front and limits potential unused material. Choose 10mg when you already need the larger total quantity and prefer the displayed value per milligram.
Is Tesamorelin better than CJC-1295 / Ipamorelin?
Tesamorelin has stronger human evidence for visceral-fat reduction. CJC-1295 / Ipamorelin is a fixed two-pathway blend more commonly compared for broader GH-axis, recovery, sleep, and body-composition hypotheses. The better fit depends on the question being researched.
What side effects were monitored with Tesamorelin?
Trials and prescription labeling discuss injection-site reactions, swelling, joint or limb discomfort, muscle pain, increased IGF-1, hypersensitivity, and glucose-related concerns. Individual medical screening matters because Tesamorelin affects the GH and IGF-1 axis.
Is this product the same as Egrifta?
No. Egrifta is an authorized prescription formulation with specific manufacturing controls, excipients, indications, and clinical instructions. A lyophilized research vial is not interchangeable with Egrifta.
